2017 Review: Progress in Using Human Stem Cells in the Treatment of Autism Spectrum Disorder

Friedrich K. Weddige


Autism and Autism Spectrum Disorders are a set of heterogeneous and enigmatic neurodevelopmental pathologies that arise from a variety of triggers.  In spite of outstanding scientific achievements in the study of the pathologies associated with autism and autism spectrum disorders, as of 2017 these developmental disorders are still without a curative treatment option.  This analysis reviews the therapeutic characteristics of stem cells and how they can provide clinical application and novel treatment options for autism spectrum disorders.  This review integrates a concise evaluation of all stem cell types utilized in autism research and treatment and associates the efficacy, safety, and tolerability findings of the most current stem cell-autism spectrum disorder treatments.  Concluding data outlines budgetary and funding rates associated with stem cell-autism spectrum disorder research (2012-2017) and concludes with avenues for novel research and treatment options.   


stem cell; autism; autism spectrum disorder; umbilical cord; stem cell treatment; mesenchymal stem cell.

Full Text:



American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM -5. Washington, D.C: American Psychological Association, 2013, pp. 52.

“Autism.” Internet: www.stemcellgeneticmed.com, New Florida Marketing, 2017 [May 2, 2017].

“Autism treatment.” Internet: https://www.emcell.com/en/list_of_diseases/autism_treatment.htm , [May 2, 2017].

J. Baio. “Prevalence of autism spectrum disorders – Autism and developmental disabilities monitoring network, 14 sites, United States, 2008.” MMWR Surveillance Summit, vol. 61(SS03), pp. 1-19, March 2012.

Beike Technology. “Stem Cell Treatment for Autism / ASD.” Internet: https://stemcelltreatmentnow.com/treatments/stem-cell-treatment-autism/ , 2017 [May 10, 2017].

G. Bjorklund, K. Saad, S. Chirumbolo, J.K. Kern, D.A. Geier, M.R. Geier, et al. “Immune dysfunction and neuroinflammation in autism spectrum disorder.” Acta Neurobiologiae Experimentalis (Wars), vol 76(4), pp. 257-68, 2016.

J.J. Bradstreet, S. Smith, M. Baral, D.A. Rossignol. “Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder.” Alternative Medicine Review, vol. 15(1), pp. 15-32, April 2010.

J.J. Bradstreet, N. Sych, N. Antonucci, M. Klunnik, O. Ivankova, I. Matyashchuk, et al. “Efficacy of fetal stem cell transplantation in autism spectrum disorders: An open-labeled pilot study.” Cell Transplantation, vol. 23(1), pp. S105-S112, 2014.

M.L. Bustos, L. Huleihel, M.G. Kapetanaki, C.L. Lino-Cardenas, L. Mroz, B.M. Ellis, et al. “Aging mesenchymal stem cells fail to protect because of impaired migration and antiinflammatory response.” American Journal of Respiratory and Critical Care Medicine, vol. 189(7), pp. 787–98, April 2014.

Center for Disease Control and Prevention. “Autism Spectrum Disorders – Data & Statistics.” Internet: https://www.cdc.gov/ncbddd/autism/data.html , Jul. 11, 2016 [Aug. 6, 2016].

Y.K Chang, M-H. Chen, Y-H. Chiang, Y-F. Chen, W-H. Ma, C-Y. Tseng, et al. “Mesenchymal stem cell transplantation ameliorates motor function deterioration of spinocerebellar ataxia by rescuing cerebellar Purkinje cells.” Journal of Biomedical Science, vol. (18)1, article 54, May 2011.

S.H. Chen, F.M. Chang, Y.C. Tsai, K.F. Huang, C.L. Lin, M.T. Lin. “Infusion of human umbilical cord blood cells protect against cerebral ischemia and damage during heatstroke in the rat.” Experimental Neurology, vol. 199(1), pp. 67-76, May 2006.

G. Dawson, J.M. Sun, K.S. Davlantis, M. Murias, L. Franz, J. Troy, et al. “Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase I open-label trial.” Stem Cells Translational Medicine, vol. 6(5), pp. 1332-9, May 2017.

D. Drago, C. Cossetti, N. Iraci, E. Gaude, G. Musco, A. Bachi, et al. “The stem cell secretome and its role in brain repair” Biochimie, vol. 95(12), pp. 2271-85, Dec 2013.

Duke Center for Brain Development and Autism. “Efficacy of Umbilical Cord Blood Infusion for Improving Outcomes of Children with Autism Spectrum Disorder: DukeACT.” Internet: http://autismcenter.duke.edu/research/efficacy-umbilical-cord-blood-infusion-improving-outcomes-children-autism-spectrum-disorder, 2015 [August 10, 2017].

A.M. Enstrom, C.E. Onore, J.A. Van de Water, P. Ashwood. “Differential monocyte responses to TLR ligands in children with autism spectrum disorders.” Brain, Behavior, and Immunity, vol. 24(1), pp. 64–71, Jan. 2010.

Y.C Hsu, D.C. Lee, I.M. Chiu. “Neural stem cells, neural progenitors, and neurotrophic factors.” Cell Transplantation, vol. 16(2), pp. 133–50, 2007.

T.E. Ichim, F. Solano, E. Glenn, F. Morales, L. Smith, G. Zabrecky, N.H. Riordan. (2007, Jun). “Stem cell therapy for autism.” Journal of Translational Medicine. [On-line]. 5(30). Available: https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-5-30 [Oct. 10, 2016].

P.A. Klemmt, V. Vafaizadeh, B. Groner. “The potential of amniotic fluid stem cells for cellular therapy and tissue engineering.” Expert Opinion on Biological Therapy, vol. 11(10), pp. 1297–314, Oct. 2011.

Kurtzberg, J. “Cord blood infusions for children with autism spectrum disorders (DukeACT).” Internet; https://clinicaltrials.gov/ct2/show/NCT02847182?term=duke+cordblood&rank=1, 2016 [July 13, 2017].

R. Laguna Goya, R. Busch, R. Mathur, A.J. Coles, R.A.Barker. “Human fetal neural precursor cells can up-regulate MHC class I and class II expression and elicit CD4 and CD8 T cell proliferation.” Neurobiology of Disease, vol. 41(2), pp. 407–14, Feb. 2011.

K. Le Blanc, M.F. Pittenger. (2009, Jul.).“Mesenchymal stem cells: progress toward promise.” Cytotherapy. [On-line]. 7(1), pp. 36–45. Available: http://www.tandfonline.com/doi/abs/10.1080/14653240510018118 [Aug. 16, 2017].

D. Minteer, K.G. Marra, J.P. Rubin. “Adipose-derived mesenchymal stem cells: biology and potential applications.” Advances in Biochemical Engineering and Biotechnology, vol. 129, pp. 59-71, 2013.

M. Xue, M. Brimacombe, J. Chaaban, B. Zimmerman-Bier, G.C.Wagner. “Autism spectrum disorders: concurrent clinical disorders.” Journal of Child Neurology, vol. 23(1), pp. 6-13, Jan 2008.

K. Miyake, T. Hirasawa, T. Koide, T. Kubota. “Epigenetics in autism and other neurodevelopmental diseases.” Advances in Experimental Medicine and Biology, vol. 724, pp. 91–8, 2012.

Y. Nakamura, T. Hiroyama, K. Miharada, R. Kurita. “Red blood cell production from immortalized progenitor cell line.” International Journal of Hematology, vol. 93(1), pp. 5–9, Jan. 2011.

National Institute of Health. “Budget.” Internet: https://www.nih.gov/about-nih/what-we-do/budget, 2017 [Aug. 16, 2016].

M.B. Newman, A.E. Willing, J.J.Manresa, C.D. Sanberg, P.R.Sanberg. “Cytokines produced by cultured human umbilical cord blood (HUCB) cells: implications for brain repair.” Experimental Neurology, vol. 199(1), pp. 201-8, May 2006.

E.S. Ng, PR. Davis, L. Azzola, E.G. Stanley, A.G. Elefanty. “Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation.” Blood, vol. 106(5), pp. 1601–3, Sept. 2005.

D.B. Noriega, H.F. Savelkoul. “Immune dysregulation in autism spectrum disorder.” European Journal of Pediatrics, vol. 173(1), pp. 33-43, Jan. 2014.

D.A. Peterson. “Umbilical cord blood cells and brain stroke injury: bringing in fresh blood to address an old problem.” Journal of Clinical Investigation, vol. 114, pp. 312-14, Aug. 2004.

C.E. Petrie Aronin, R.S. Tuan. “Therapeutic potential of the immunomodulatory activities of adult mesenchymal stem cells.” Birth Defects Research C Embryo Today, vol. 90(1), pp. 67–74, Mar. 2010.

T.A. Prokhorova, L.M. Harkness, U. Frandsen, N. Ditzel, H.D. Schrøder, J.S. Burns, et al. “Teratoma formation by human embryonic stem cells is site dependent and enhanced by the presence of Matrigel.” Stem Cells and Development, vol. 18(1), pp. 47-54, Jan-Feb. 2009.

S. Razavi, M.R. Razavi, H. Zarkesh Esfahani, M. Kazemi, F.S. Mostafavi. “Comparing brain-derived neurotrophic factor and ciliary neurotrophic factor secretion of induced neurotrophic factor secreting cells from human adipose and bone marrow-derived stem cells.” Development, Growth & Differentiation, vol. 55(6), pp. 648-55, Aug. 2013.

Regeneration Center of Thailand. “Treatment for Autism Spectrum Disorders ASD.” Internet: https://stemcellthailand.org/therapies/autism-spectrum-asd/ , 2017 [May 20, 2017].

Riordan, N. “Stem cell therapy – Autism. Stem Cell Institute.” Internet: https://www.cellmedicine.com/stem-cell-therapy-for-autism/, 2016 [Aug. 16, 2016].

R.C. Rodrigues Hell, M.M. Silva Costa, A.M. Goes, A.L. Oliveira. “Local injection of BD9NF producing mesenchymal stem cells increases neuronal survival and synaptic stability following ventral root avulsion.” Neurobiology of Disease, vol. 33(2), pp. 290–300, Feb. 2009.

P. Rubinstein, L. Dobrila, R.E. Rosenfield, J.W. Adamson, G. Migliaccio, A.R. Migliaccio, et al. “Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.” Proceedings of the National Academy of Sciences of the United States of America, vol. 92(22), pp. 10119–22, Oct. 1995.

S. Senju, S. Hirata, Y. Motomura, D. Fukuma, Y. Matsunaga, S. Fukushima, et al. “Pluripotent stem cells as source of dendritic cells for immune therapy.” International Journal of Hematology, vol. 91(3), pp. 392–400, Apr. 2010.

K. Stenderup, J. Justesen, C. Clausen, M. Kassem. “Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells.” Bone, vol. 33(6), pp. 919–26, Dec. 2003.

D. Siniscalco, J.J. Bradstreet, N. Sych, N. Antonucci. (2013). “Perspectives on the use of stem cells for autism treatment.” Stem cells International. [On-line]. 2013, pp 1-7, Article ID 262438. Internet: http://dx.doi.org/10.1155/2013/262438 [July 7, 2017].

D. Siniscalco, A. Giordano, U. Galderisi. “Novel insights in basic and applied stem cell therapy.” Journal of Cellular Physiology, vol. 227(5), pp. 2283-86, May 2012.

D. Siniscalco, C. Giordano, U. Galderisi, L. Luongo,V. de Novellis,F. Rossi, et al. (2011, Dec.). “Long-lasting effects of human mesenchymal stem cell systemic administration on pain-like behaviors, cellular, and biomolecular modifications in neuropathic mice.” Frontiers in Integrative Neuroscience. [On-line]. 5(79). Available: https://www.frontiersin.org/articles/10.3389/fnint.2011.00079/full [Aug. 15, 2017].

D. Siniscalco, A. Pandolfi, U. Galderisi. “State-of-the-art on basic and applied stem cell therapy; Stem Cell Research Italy-International Society for Cellular Therapy Europe, Joint Meeting, Montesilvano (PE)-Italy, June 10-12, 2011.” Stem Cell Development, vol. 21(5), pp. 668-9, Mar. 2012.

D. Siniscalco, A. Sapone, A. Cirillo, C. Giordano, S. Maione, N. Antonucci. (2012). “Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future?” Journal of Biomedicine and Biotechnology. [On-line]. 2012, pp. 1-7, Article ID 480289, Internet: https://www.hindawi.com/journals/bmri/2012/480289/ . [August 14, 2017].

D. Siniscalco, A. Sapone, C. Giordano, A. Cirillo, L. de Magistris, F.Rossi, et al. “Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders.” Journal of Autism and Developmental Disorders, vol. 43(11), pp. 2686-95, Nov. 2013.

D. Siniscalco, A. Sapone, C. Giordano, A. Cirillo, V. de Novellis, L. de Magistris, et al. “The expression of caspases is enhanced in peripheral blood mononuclear cells of autism spectrum disorder patients.” Journal of Autism and Developmental Disorders, vol. 42(7), pp. 1403-10. Jul. 2012.

Stem Cell Institute. “What is Autism?” Internet: https://www.cellmedicine.com/stem-cell-therapy-for-autism/ , 2016. [May 2, 2017].

C. Tang, I.L. Weissman, M. Drukker. “Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives.” Methods in Molecular Biology, vol. 1029, pp. 17-31. 2013.

H. Wegmeyer, A.M. Bröske, M. Leddin, K. Kuentzer, A. Katharina Nisslbeck, J. Hupfeld, et al. “Mesenchymal stromal cell characteristics vary depending on their origin.” Stem Cells and Development, vol. 22(19), pp. 2606–18, Oct. 2013.

V.I. Zemel'ko, I.B. Kozhukharova, L.L. Alekseenko, A.P. Domnina, G.F. Reshetnikova, M.V. Puzanov,et al. “Neurogenic potential of human mesenchymal stem cells isolated from bone marrow, adipose tissue and endometrium: a comparative study.” Tsitologiia, vol. 55(2), pp. 101-110, 2013.

G.P. Zheng, M.H. Ge, Q. Shu, M. Rojas, J. Xu. “Mesenchymal stem cells in the treatment of pediatric diseases.” World Journal of Pediatrics, vol. 9(3), pp. 197-211, Aug. 2013


  • There are currently no refbacks.





About IJSBAR | Privacy PolicyTerms & Conditions | Contact Us | DisclaimerFAQs 

IJSBAR is published by (GSSRR).